The Mosaic Cell Sciences team (a division of Organovo, Inc.) is comprised of experts in the field of primary human cell isolation and culture with over 45 years of combined experience. Our scientists have isolated cells from over 2,000 healthy and diseased organs and tissues. With our mission to advance the scientific discoveries of our partners' and clients' research and discovery programs, our scientific and technical support teams offer the utmost quality for your workflows to improve the lives of patients. 

Mosaic Cell Sciences' donor-derived cells, in combination with Organovo's experience with 3D tissue and organ systems, have translated into a clinical trial for Organovo's lead target for Inflammatory Bowel Disease. Our offerings of healthy and diseased primary human cells allow scientists to recreate the heterogeneity and pathophysiology responsible for liver disease and IBD. With our primary human cell solutions you can generate translational in vitro models to advance your discoveries into the clinic. 

Mosaic Cell Sciences,
Your Puzzle Pieces to Discovery!"

Kenneth Dorko Senior Director for Cell Processing and Commercial development Kenneth brings more than 30 years of hepatocyte transplantation and isolation experience from academia and industry to Mosaic Cell Sciences and is recognized as a world leader in liver cell isolation and their use for therapeutic and research purposes. He currently leads the cell processing and commercial development team at Mosaic Cell Sciences, a division of Organovo Inc. Prior to Mosaic Cell Sciences, Kenneth served as Director of Process Development and Manufacturing at Ambys Medicines, a start-up company focused on the treatment of patients with severe liver disease through hepatocyte therapy. Kenneth was also the Associate Director of Technical Operations at Samsara Sciences, a human liver cell isolation company that provided multiple liver cell types from normal and diseased livers to biotech, pharma, and academic centers across the US. Kenneth’s previous experience includes 3 years at the University of Kansas Medical Center in Kansas City, where in the role of Technical Director he established the hepatocyte core lab. He also spent 19 of his 22 years at the University of Pittsburgh in the laboratory of Dr. Stephen Strom, one of the pioneers in human hepatocyte transplantation. Kenneth and Dr. Strom, together with Dr. Ira Fox, established the first FDA approved academic lab for the isolation of human hepatocytes for clinical applications. Kenneth earned a BS in Biochemistry and Biophysics from the University of Pittsburgh, Pittsburgh, PA.